Seaport Therapeutics Q1 2026 Earnings Results & Report

Seaport Therapeutics EPS Results

• Actual EPS: -$10.34
• Consensus EPS: -$10.64
• Beat/Miss: Beat by +$0.30
• One Year Ago EPS: N/A

Seaport Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Seaport Therapeutics (NASDAQ:SPTX) is a clinical-stage biopharmaceutical company focused on developing medicines for neuropsychiatric and neurological disorders. The company’s research emphasizes therapies that modulate the brain’s GABAergic system, which plays an important role in mood, anxiety, and other central nervous system functions.

Seaport’s drug-development programs are based on its Glyph platform, a technology designed to improve the delivery of small-molecule medicines to the brain and enable oral versions of therapies that may otherwise require intravenous or other forms of administration. Its pipeline includes SPT-300, an oral neuroactive steroid prodrug being developed for psychiatric indications, along with additional investigational programs targeting central nervous system disorders.

The company was established as a biotechnology venture backed by PureTech Health and is headquartered in the United States. Seaport is led by founder and Chief Executive Officer Daphne Zohar. As a clinical-stage company, Seaport’s activities are primarily centered on research, clinical development, and advancing its pipeline toward potential regulatory approval in the United States and other markets.